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5% of all ovarian tumours are accounted to germ cell tumours (GCT’s). 
Affecting mostly young women, the highest incidence is seen in second 
and third decade of life. They are highly malignant but chemosensitive 
and more curable than their epithelial counterparts. Treating these tumors 
with effective surgery and combination chemotherapy survival rates have 
dramatically improved in recent decades. We present our experience 
of ovarian germ cell tumours in the department of Surgical Oncology, 
Rajendra Institute of Medical Sciences (RIMS), Ranchi with special 
emphasis on treatment outcomes. A retrospective review of hospital med-
ical records of patients with ovarian germ cell tumours diagnosed and 
treated at RIMS from June 2019 to August 2020, was performed. Clinical 
profile and treatment outcome of patients were recorded. A total of 19 
patients met criteria. The median age at diagnosis was 20 years (range 11-
42 years) and all had good performance status. All except two patients 
underwent surgery, 70.6% and 29.4% in upfront and interval debulking 
surgery (IDS) setting respectively. Fertility preserving surgery was done 
in 75% patients in the primary surgery group and 60% undergoing IDS. 
83.3% patients received BEP as adjuvant chemotherapy whereas 80% as 
neo-adjuvant chemotherapy. 
Majority (31.5%) patients had dysgerminoma as final histology, followed 
by mixed histology(26.3%), yolk sac tumour (15.7%), immature teratoma 
(15.7%) and choriocarcinoma (10.5%). 47.3% patients were in Stage I at 
the time of diagnosis. 78.9% patients were alive without disease, 10.5% 
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1. Introduction
20 to 25% of all benign and malignant ovarian neo-
plasms are of germ cell origin. These are uncommon 
neoplasms arising from primitive germ cells of the embry-
onic gonad. Affecting mostly young women, the highest 
incidence is seen in second and third decade of life. Most 
common histology is teratoma followed by dysgerminoma 
worldwide. 
Before mid 1960’s, almost all non-dygerminomatous 
18
Journal of Oncology Research | Volume 03 | Issue 01 | January 2021
Distributed under creative commons license 4.0
GCT patients died. The patients with dysgerminoma 
survived owning to its high radiosensitivity but fertility 
was not spared. The introduction of combination che-
motherapy VAC (vincristine, dactinomycin, and cyclo-
phosphamide) achieved 85% cure rate in stage I GCT’s 
whereas metastatic disease had a 50-70% [1-2] mortality. 
Moreover as BEP therapy does not effect ovarian func-
tion much, most GCT patients remain fertile and are 
able to give birth[3-6]. FIGO stage and elevated tumour 
markers are seen to be independent poor prognostic in-
dicators [7]. 
2. Materials and Methods 
This is a retrospective study in which data was col-
lected prospectively from hospital medical records. All 
patients with histologically confirmed GCT and treated at 
RIMS from June 2019 to August 2020 were included. A 
total number of 19 patients met criteria.
Clinical profile, stage of presentation, histological 
classification and treatment received (primary surgery 
followed by chemotherapy or neo-adjuvant chemotherapy 
followed by interval debulking surgery) was seen. Treat-
ment outcome and disease free interval were ascertained.
The data was analysed using SPSS software. 
3. Results
During this 14 month period, a total of 19 patients were 
admitted and treated in our department. The median age 
was 20 years (range 11-42yrs) out of which one patient 
was premenarchal. All patients had a performance status 
of ECOG 0/1. The median AFP at presentation was 986 
ng/mL (range 11-23000 ng/mL), median LDH 843 U/L 
(range 273-15000 U/L). All except two patients had nor-
mal β-hCG (table 1).
Stage wise distribution is depicted in Figure 1. Major-
ity patients(n=9; 47.3%) belonged to stage I followed by 
stage III (n= 11; 26.3%). Two patients belonged to stage II 
and three to stage IV. 
Table 1. Demographics
Median Age 20 (11-42years)
PS All except 1 were ECOG 0/1
Tumour markers at presentation
AFP 986 (11-23,000)
LDH 843 (273-15000)
bHCG Normal in all except 2
12 (70.6%) patients underwent upfront surgery out of 
which 9 (75%) had fertility preservation and 3 (25%) had 
radical surgery. 
In terms of adjuvant chemotherapy, 10 (83.3%) patients 
received BEP to begin with following which 3 (30%) 
were switched to EP due to bleomycin induced toxicity, 2 
(16.6%) patients received EP, whereas 1 (8.3%) received 
VIP after disease progression on BEP. 
Table 3. Interval debulking surgery details











Table 2. Upfront surgery details





Fertility not preserved TAH BSO/omentectomy/LND 2
7 patients received neo-adjuvant chemotherapy (4 BEP 
followed by VIP in 1 patient, 1 EP and 2 single agent 
Methotrexate) following which 5 underwent interval 
debulking surgery (2 patients had choriocarcinoma which 
DOI: https://doi.org/10.30564/jor.v3i1.2705
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was cured with chemotherapy). The reasons for NACT 
were extensive disease in 2 patients out of which 1 patient 
also had portal vein thrombosis, poor PS in 2 patients, 
whereas 1 patient had already received NACT before she 
presented to us. Among the 5 patients undergoing interval 
debulking surgery 3 had fertility preservation. Complete 
cytoreduction of macroscopic disease was achieved in all 
patients who underwent surgery.
Among the 10 patients receiving adjuvant BEP che-
motherapy following upfront surgery, majority received 
4 cycles (6 patients) out of which 2 patients received sub-
sequent 2 cycles of EP, 3 patients received 3 cycles out 
of which 1 received subsequent 2 cycles of EP and 1 re-
ceived additional 3 cycles of VIP. 1 patient was switched 
to 3 cycles of EP regimen after the first cycle of BEP due 
to bleomycin toxicity and 2 patients received 4 cycles of 
EP.
In the interval debulking surgery group, 3 patients re-
ceived 3 cycles of BEP, 1 received 4 cycles BEP whereas 
1 received 1st cycle as single agent carboplatin followed 
by 4 cycles EP as NACT. The patients with choriocarcino-
ma received 4 cycles of single agent methotrexate. Post-
operatively 2 patients received 2 cycles EP whereas the 
rest did not need adjuvant treatment.
Table 4. Chemotherapy details










Table 5. Chemotherapy cycles













19 (47.5%) patients had yolk sac tumour, 11 patients 
had mixed histology, 5 presented with dysgerminoma, 4 
with immature teratoma whereas 1 patient had choriocar-
cinoma as depicted in figure 2.
Figure 2.
Follow up data was available for n= 17 patients. This 
data revealed 15 patients alive without disease and 2 pa-
tients alive with disease. 2 patients developed recurrence 
and 2 were lost to follow up. None of the patients died 
during this period.
In the recurrence group, one patient had recurrence in 
both abdomen and pelvis whereas another one in abdomen 
and thorax. Both received second-line chemotherapy. Two 
patients were lost to follow up.
4. Discussion
Though accounting for only 5% of all malignant neo-
plasms, their impact in patient’s life is enormous since it 
mostly affects women in their second or third decade of 
life [8] . Fearing the sequelae of the disease, many women 
choose radical surgery but it has been seen that fertility 
sparing surgery is also an equally effective treatment with 
possibility of future childbearing [9]. It is now possible to 
achieve complete cure with fertility preservation however 
reports on reproductive outcome of GCT survivors are 
sporadic since it has been only around 30 years since this 
dramatic improvement due to the implementation of BEP 
chemotherapy [3-6]. However Zhang et al. in their retro-
spective study of 32 patients with malignant ovarian germ 
cell tumour (MOGCT) and sex cord stromal tumours 
(SCST) showed fertility sparing surgery to be an equally 
effective alternative to radical surgery with the advantage 
of menstrual and fertility preservation [10]. In their series 
all patients underwent fertility sparing surgery (FSS) 
whereas we could achieve 70.5% FSS rate. This could be 
due to the fact that all except one patient in their series 
belonged to either stage I or II whereas 42.1% patients in 
our series had stage III-IV disease. In addition to a desire 
to cure, a desire to become pregnant also improves treat-
ment outcomes [25].
Similarly, Turkmen et al. in their series of 69 patients 
compared survival outcomes of patients undergoing con-
servative surgery with definitive surgery and established 
DOI: https://doi.org/10.30564/jor.v3i1.2705
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surgery type to be insignificant for recurrence [11]. Other 
studies have also shown that fertility sparing surgery did 
not affect cancer prognosis in cases of advanced germ cell 
tumours [6,26,27].
Maheshwari A et al. [12] in their report from India,stat-
ed dysgerminoma as the most common histological type 
which is similar to our series of patients.
Though majority of patients belonged to stage I, a con-
siderable number of patients presented in the advanced 
stage. This is due to proper staging surgeries performed 
at our centre along with late referral from other non-on-
cologic treating institutes. Many patients were operated 
outside without suspicion of malignancy and presented to 
us with suspicious final histopathology. One patient with 
advanced disease even received neo-adjuvant chemother-
apy outside before presenting to us. BEP chemotherapy is 
effective for treating germ cell tumors of the ovary and it 
has been validated in several trials [13-15]. 
In the NACT setting, there was complete pathologi-
cal(or radiological) response in 66.67% patients whereas 
the rest showed partial response according to the RECIST 
criteria. S Talukdar et al [16] in their series of 23 patients 
receiving NACT also showed a complete response of 
60.5%. Literature reports 40.7% complete pathological 
response [17].
10.5% patients recurred and were managed with second 
line chemotherapy such as VIP (etoposide, ifosfamide, 
and cisplatin).
Most patients with early disease and healthy looking 
uterus and ovary underwent fertility sparing surgery. In 
cases of normal looking contralateral ovary, routine bi-
opsy was not taken however it was thoroughly palpated 
and any suspicious nodules biopsied. Although occult 
bilaterality has been reported, biopsy of the contralateral 
ovary could lead to future infertility related to peritoneal 
adhesions or ovarian failure [18,19]. Unlike their epithelial 
ovarian counterparts, GCT’s are amenable to fertility pres-
ervation. Hence it shoud be the standard of care whenever 
possible. Many studies document good outcome in this 
regard [20-24].
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